The application effect of percutaneous cryoablation for the stage IIIB/IV advanced non-small-cell lung cancer after the failure of chemoradiotherapy

被引:11
作者
Gao, Wei [1 ,2 ,3 ]
Guo, Zhi [1 ,2 ,3 ]
Shu, Shumiao [4 ]
Xing, Wenge [1 ,2 ,3 ]
Zhang, Weihao [1 ,2 ,3 ]
Yang, Xueling [1 ,2 ,3 ]
机构
[1] Tianjin Med Univ, Dept Intervent Therapy, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjin, Peoples R China
[2] Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
[3] Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China
[4] Tianjin Univ Tradit Chinese Med, Dept Chinese Med, Tianjin, Peoples R China
基金
美国国家科学基金会;
关键词
Cryoablation; Lung cancer; Stage IIIB/IV; PALLIATIVE THORACIC RADIOTHERAPY; RADIOFREQUENCY ABLATION; FUNCTIONAL ASSESSMENT; RANDOMIZED-TRIAL; PHASE-III; CHEMOTHERAPY; THERAPY; MANAGEMENT; SAFETY;
D O I
10.1016/j.asjsur.2018.02.006
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background/Objective: A retrospective review is required to assess the application effect of percutaneous cryoablation on the stage IIIB/IV advanced non-small-cell lung cancer (NSCLC) after the failure of chemoradiotherapy. A total of twenty-two cases with stage IIIB/IV advanced NSCLC after failure of chemoradiotherapy were enrolled. Methods: Computed Tomography (CT) was used for the assessment of tumor response, and Functional Assessment of Cancer Therapy-General (FACT-G) was applied for the evaluation of quality of life. After the treatment of cryoablation, we performed a follow-up analysis. Results: The primary technique effectiveness of 100% was observed in the one month of follow-up. At three months, local tumor progression was shown in 4 of 31 lesions (13.6%). The one-year survival rate of 81.8% and progression-free rate of 27.8% were obtained. Six patients died 7, 9, 10, 12, 15 and 22 months after treatment, respectively. Decreased scores of total quality of life at one week after cryoablation (P = 0.006), but increased scores at one month after cryoablation (P = 0.024) were observed, compared with pre-cryoablation. Conclusion: Cryoablation contributes to the effective local tumor therapy for stage IIIB/IV advanced NSCLC after the failure of chemoradiotherapy. (C) 2018 Asian Surgical Association and Taiwan Robotic Surgery Association. Publishing services by Elsevier B.V.
引用
收藏
页码:530 / 536
页数:7
相关论文
共 50 条
  • [1] Comparing cryoablation and microwave ablation for the treatment of patients with stage IIIB/IV non-small cell lung cancer
    Das, Sushant Kumar
    Huang, Ya-Yong
    Li, Bing
    Yu, Xiao Xuan
    Xiao, Ru Hui
    Yang, Han Feng
    ONCOLOGY LETTERS, 2020, 19 (01) : 1031 - 1041
  • [2] Chemotherapy of stage IIIB and IV non-small-cell lung cancer
    Cojean, I
    LeChevalier, T
    ANNALS OF ONCOLOGY, 1995, 6 : 41 - 44
  • [3] Cisplatin-based chemotherapy in elderly patients with advanced stage (IIIB and IV) non-small cell lung cancer patients
    Ozkaya, S.
    Findik, S.
    Atici, A. G.
    Dirican, A.
    NEOPLASMA, 2011, 58 (04) : 348 - 351
  • [4] Neoadjuvant chemoradiotherapy followed by surgery for stage IIIa and IIIb non-small-cell lung cancer (NSCLC): is it still justified?
    Mirimanoff, Rene-Olivier
    CHINESE CLINICAL ONCOLOGY, 2015, 4 (04)
  • [5] Novel Chemoradiotherapy With Concomitant Boost Thoracic Radiation and Concurrent Cisplatin and Vinorelbine for Stage IIIA and IIIB Non-Small-Cell Lung Cancer
    Imamura, Fumio
    Konishi, Koji
    Uchida, Junji
    Nishino, Kazumi
    Okuyama, Takako
    Kumagai, Toru
    Kawaguchi, Yoshifumi
    Nishiyama, Kinji
    CLINICAL LUNG CANCER, 2014, 15 (04) : 281 - 286
  • [6] THE COMBINATION OF MITOMYCIN, VINBLASTINE AND CISPLATIN IS ACTIVE IN THE PALLIATION OF STAGE-IIIB-IV NON-SMALL-CELL LUNG-CANCER
    VINANTE, O
    BARI, M
    SEGATI, R
    AZZARELLO, G
    SAMPOGNARO, E
    ROSETTI, F
    PAPPAGALLO, GL
    ONCOLOGY, 1993, 50 (01) : 1 - 4
  • [7] Use of Cetuximab After Failure of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer
    Wu, Jenn-Yu
    Yang, Chih-Hsin
    Hsu, Ya-Chieh
    Yu, Chong-Jen
    Chang, Shih-Han
    Shih, Jin-Yuan
    Yang, Pan-Chyr
    CLINICAL LUNG CANCER, 2010, 11 (04) : 257 - 263
  • [8] Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer
    Jung, Hyun Ae
    Noh, Jae Myoung
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Pyo, Hongryull
    Ahn, Yong Chan
    Park, Keunchil
    LUNG CANCER, 2020, 146 : 23 - 29
  • [9] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
    Carbone, D. P.
    Reck, M.
    Paz-Ares, L.
    Creelan, B.
    Horn, L.
    Steins, M.
    Felip, E.
    van den Heuvel, M. M.
    Ciuleanu, T. -E.
    Badin, F.
    Ready, N.
    Hiltermann, T. J. N.
    Nair, S.
    Juergens, R.
    Peters, S.
    Minenza, E.
    Wrangle, J. M.
    Rodriguez-Abreu, D.
    Borghaei, H.
    Blumenschein, G. R.
    Villaruz, L. C.
    Havel, L.
    Krejci, J.
    Corral Jaime, J.
    Chang, H.
    Geese, W. J.
    Bhagavatheeswaran, P.
    Chen, A. C.
    Socinski, M. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) : 2415 - 2426
  • [10] Analysis of Relapse Events After Definitive Chemoradiotherapy in Locally Advanced Non-Small-Cell Lung Cancer Patients
    Grass, G. Daniel
    Naghavi, Arash O.
    Abuodeh, Yazan A.
    Perez, Bradford A.
    Dilling, Thomas J.
    CLINICAL LUNG CANCER, 2019, 20 (01) : E1 - E7